» Articles » PMID: 31986411

Transcriptional Regulation of PRKAR2B by MiR-200b-3p/200c-3p and XBP1 in Human Prostate Cancer

Overview
Date 2020 Jan 28
PMID 31986411
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway is profoundly implicated in Prostate cancer (PCa) progression. Previously, we showed that PRKAR2B, the type II-beta regulatory subunit of PKA, is highly expressed in castration-resistant prostate cancer (CRPC) and can induce epithelial-mesenchymal transition by activating Wnt/β-catenin signaling in PCa cells. However, the molecular mechanism of dysregulated PRKAR2B expression pattern is still largely unknown. In this study, we found that the mutation, copy number alteration, and methylation status of PRKAR2B gene have no correlation with its expression level in PCa. Then, we identified two microRNAs (miR-200b-3p and miR-200c-3p) to be critical regulators of PRKAR2B expression in PCa. Notably, miR-200b-3p and miR-200c-3p expression were significantly downregulated in metastatic CRPC and negatively correlated with the expression level of PRKAR2B in PCa tissues. Moreover, we characterized X-Box Binding Protein 1 (XBP1) as a key transcription factor responsible for PRKAR2B expression in PCa. Importantly, miR-200b-3p/200c-3p or XBP1 knockdown inhibited PCa cell proliferation and promoted cell apoptosis and these inhibitory roles could be largely restored by PRKAR2B, suggesting that PRKAR2B is a functional mediator of miR-200b-3p, miR-200c-3p, and XBP1 in PCa. Collectively, our study firstly identified miR-200b-3p/200c-3p and XBP1 as the critical upstream regulators of PRKAR2B in PCa and provided novel insights to PRKAR2B-driven PCa progression.

Citing Articles

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.

Jian J, Wang X, Zhang J, Zhou C, Hou X, Huang Y Front Endocrinol (Lausanne). 2024; 15:1360430.

PMID: 38887275 PMC: 11180744. DOI: 10.3389/fendo.2024.1360430.


Revisiting the roles of cAMP signalling in the progression of prostate cancer.

Parsons E, Hoffmann R, Baillie G Biochem J. 2023; 480(20):1599-1614.

PMID: 37830741 PMC: 10586777. DOI: 10.1042/BCJ20230297.


Integrative analysis of the SOX family-related prognostic signature and immunological infiltration in prostate cancer.

Li Z, Wang F Transl Cancer Res. 2023; 12(8):2048-2062.

PMID: 37701109 PMC: 10493808. DOI: 10.21037/tcr-23-501.


Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4.

Dahal S, Chaudhary P, Kim J Cell Oncol (Dordr). 2023; 46(4):1113-1126.

PMID: 36995683 DOI: 10.1007/s13402-023-00803-y.


MAPKAPK2-centric transcriptome profiling reveals its major role in governing molecular crosstalk of IGFBP2, MUC4, and PRKAR2B during HNSCC pathogenesis.

Soni S, Anand P, Swarnkar M, Patial V, Tirpude N, Padwad Y Comput Struct Biotechnol J. 2023; 21:1292-1311.

PMID: 36817960 PMC: 9929207. DOI: 10.1016/j.csbj.2023.01.039.